Stock RLMD RELMADA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Relmada Therapeutics, Inc. OTC Markets

Equities

RLMD

US75955J4022

Real-time Estimate Cboe BZX
Other stock markets
 01:34:09 2024-07-17 pm EDT 		5-day change 1st Jan Change
3.665 USD 0.00% Intraday chart for Relmada Therapeutics, Inc. +8.91% +139.13%
Jul. 01 Relmada Therapeutics, Inc.(NasdaqGS:RLMD) added to Russell Microcap Growth Index CI
Jul. 01 Relmada Therapeutics, Inc.(NasdaqGS:RLMD) added to Russell 3000E Growth Index CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Goldman Sachs Downgrades Relmada Therapeutics to Sell From Neutral With $2 Price Target
MT
SVB Securities Cuts Price Target on Relmada Therapeutics to $10 From $42, Maintains Outperform Rating
MT
Oppenheimer Reiterates Relmada Therapeutics Perform Rating, Removes $7 Price Target
MT
Goldman Sachs Downgrades Relmada Therapeutics to Neutral From Buy, Adjusts Price Target to $8 From $81
MT
Guggenheim Downgrades Relmada Therapeutics to Neutral From Buy
MT
Truist Securities Downgrades Relmada Therapeutics to Hold From Buy, Adjusts Price Target to $10 From $90
MT
Oppenheimer Downgrades Relmada Therapeutics to Perform From Outperform, Adjusts Price Target to $7 From $64
MT
Goldman Sachs Adjusts Price Target on Relmada Therapeutics to $81 From $49, Reiterates Buy Rating
MT
Guggenheim Adjusts Price Target on Relmada Therapeutics to $60 From $50, Reiterates Buy Rating
MT
Goldman Sachs Adjusts Price Target for Relmada Therapeutics to $49 From $47, Maintains Buy Rating
MT
Oppenheimer Adjusts Relmada Therapeutics' Price Target to $64 From $75, Maintains Outperform Rating
MT
Goldman Sachs Adjusts Relmada Therapeutics' Price Target to $53 from $69, Keeps Buy Rating
MT
SVB Leerink Adjusts Relmada Therapeutics' Price Target to $42 from $50, Keeps Outperform Rating
MT
Mizuho Securities Starts Relmada Therapeutics at Buy With $50 Price Target
MT
RELMADA THERAPEUTICS : Truist Securities Adjusts Relmada Therapeutics PT to $90 From $75, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RLMD Stock
  4. RLMD Stock
  5. News Relmada Therapeutics, Inc.
  6. Analyst Reco.